Does Glaucoma Cause Loss of Brain Function?
The purpose of the study is to determine if glaucoma is associated with neurodegenerative changes in areas of the brain other than the occipital lobe. This will help guide the direction of further research in the use of neuroprotective agents in preventing or controlling such changes. The final goal is to improve the quality of life for patients with glaucoma.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Neuroimaging Brain Changes in Glaucoma|
- Brain atrophy [ Time Frame: 2 days ] [ Designated as safety issue: No ]Mini-Mental State Exam and T-1 weighted MRI brain scan and will be performed
|Study Start Date:||August 2010|
|Study Completion Date:||March 2012|
|Primary Completion Date:||March 2012 (Final data collection date for primary outcome measure)|
Patients who were outliers from the AARV or ADREV Studies.
Age, gender and race matched group of healthy individuals with no ocular diseases.
Death of retinal ganglion cells causes loss of neurons in areas other than just the visual cortex. These neurodegenerative changes decrease the patient's ability to perform the activities of daily living. Tensor-based morphometry analysis of MRI brain scans will reveal areas of cortical degeneration in glaucoma patients, and the extent of damage in these areas will correlate with their ability to perform vision-dependent tasks, as measured by the Assessment of Ability Related to Vision (AARV).
Patients with glaucoma who were outliers in Assessment of Ability Related to Vision (AARV) Study or Assessment of Disability related to vision (ADREV) Study, in that they have poor performance-based measure scores despite having midrange visual field scores.
Mini-Mental State Exam and T-1 weighted MRI brain scan and will be performed.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01303939
|United States, Pennsylvania|
|Wills Eye Institute, Glaucoma Service|
|Philadelphia, Pennsylvania, United States, 19107|
|Principal Investigator:||George L Spaeth, MD||Glaucoma Service, Wills Eye Institute|